**Core tip:** It is essential to reduce discomfort in esophagogastroduodenoscopy. The present study clearly identified the factors associated with discomfort in esophagogastroduodenoscopy using a large-size cross-sectional study. Young age, female sex, and current smoking were identified as the contributive factors. Smoking status was a newly identified predictor of this study. Furthermore, heavy alcohol consumption was noted to diminish the effect of the sedative(s). These factors are useful because they can be easily obtained, and we can take remedial measures for reducing discomfort.

INTRODUCTION
============

Esophagogastroduodenoscopy often causes discomfort in patients. Discomfort due to the endoscope contributes to a negative experience and reduces the patient's satisfaction\[[@B1],[@B2]\]. Therefore, it is important to reduce discomfort as much as possible. Sedation is mainly considered as a method to reduce such discomfort; however, due to the cost and risk of complications, the consensus is to perform endoscopy without sedation in appropriately selected patients\[[@B3]\]. To identify the patients who are likely to have marked discomfort, so that they can be considered for sedation, the predictive factors of discomfort must be ascertained. In previous studies, young age\[[@B4]-[@B7]\], female sex\[[@B4],[@B5],[@B8],[@B9]\], anxiety before the examination\[[@B4],[@B5],[@B6],[@B9]\], and pharyngeal sensitivity\[[@B6],[@B7]\] were identified as factors that increased the discomfort of transoral esophagogastroduodenoscopy; however, all factors have not yet been elucidated. Most previous studies have conducted investigations only in several hundred subjects, which is a relatively small sample. The aim of this study was to elucidate the contributing factors of discomfort in transoral esophagogastroduodenoscopy by a large-scale cross-sectional study, using easily available information from a regular endoscopy examination practice.

MATERIALS AND METHODS
=====================

Ethical considerations
----------------------

This study was reviewed and approved by the Institutional Review Board of Kameda Medical Center. Since this was a retrospective observational study, using already existing data, and did not include invasive interventions, the requirement for informed consent from the study participants was waived by the Institutional Review Board. However, written informed consent for endoscopy was obtained at the time of the procedure. The study protocol was published on the hospital's website. This study's methods are in accordance with the Japanese "Ethical Guidelines for Medical and Health Research Involving Human Subjects".

Study population and methods
----------------------------

All consecutive patients who had undergone screening transoral esophagogastroduodenoscopy at a health check-up center associated with a general hospital between August 2017 and October 2017 were included. The discomfort experienced by the patients during examination was evaluated using a questionnaire subsequent to either completion of the examination or recovery from sedation. Originally, the questionnaires were intended for the improvement of hospital services to the patients; the questionnaire results and medical records of the patients were utilized for this study. Accordingly, participants with inadequate responses in the questionnaire were excluded. In order to increase the statistical accuracy of this study, the data was collected from the largest sample size possible.

In preparation for endoscopy, dimethicone (Barugin antifoam solution; Kaigen Pharmaceutical Co., Ltd.; Osaka, Japan) containing pronase (PronaseMS; Kaken Pharmaceutical Co., Ltd.; Tokyo, Japan) and sodium bicarbonate (Yoshida Pharmaceutical Co., Ltd.; Tokyo, Japan) were administered orally. For topical pharyngeal anesthesia, 8% lidocaine spray (Xylocaine Pump Spray 8%; Aspen Japan Co., Ltd.; Tokyo, Japan) was administered. The decision to administer an antispasmodic agent depended on the endoscopist; when administered, intravenous injection of 10 mg butylscopolamine (Scopolamine butylbromide; Nichi-Iko Pharmaceutical Co., Ltd.; Tokyo, Japan) was used. Sedatives were administered upon the request of the patients and with the permission of the doctor; accordingly, an intravenous injection of pethidine (Takeda Pharmaceutical Company Ltd.; Tokyo, Japan) was predominantly used, sometimes in combination with midazolam (Sandoz Co., Ltd.; Tokyo, Japan); however, midazolam was rarely used alone. Sedation was induced prior to scope insertion. Patients expected to drive were not administered any sedatives, even upon request. The endoscope used either the GIF-PQ260, GIF-Q260, or GIF-H290 (Olympus Corporation, Tokyo, Japan). The number of endoscopists who conducted the examination was 27. The esophagus, stomach, and partial duodenum were endoscopically observed. The mouthpiece for endoscopic examination had a tube capable of aspirating saliva continuously.

The questionnaire was distributed to the patients at a different location from the endoscopy unit, by staff other than the ones who performed the endoscopy. Discomfort was evaluated on a face scale of 0 to 10 on a 6-level questionnaire (Figure [1](#F1){ref-type="fig"}).
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Statistical analysis
--------------------

Since the discomfort scores had a non-normal distribution, the median and interquartile ranges were calculated for all cases. In addition, the proportion of high discomfort (score ≥ 6) was calculated. Age, sex, height, body mass index, smoking status, alcohol intake, hiatal hernia, history of gastrectomy, biopsy performed during examination, administration of Lugol's solution, administration of butylscopolamine with/without a sedative (pethidine, midazolam, or both), endoscope model, history of endoscopy, and endoscopists were considered as probable factors of discomfort. Based on the smoking status to the participants were classified as current-smoker, past-smoker and non-smoker. Classification based on alcohol consumption included non-drinker, never to rare drinking; heavy drinker, ≥ 40 mg/d of alcohol for ≥ 3 d/wk; and the rest as normal drinker. GIF-Q260 and GIF-H290 with a diameter of 9.2 mm and 8.9 mm, respectively, defined as a normal diameter, and GIF-PQ260 with 7.9 mm, defined as a small diameter, were the endoscope models used. The participants were divided into subgroups: Sedated and non-sedated, which was expected to be strongly related to discomfort. The median discomfort score and the proportion of high discomfort (score ≥ 6) were calculated for each factor, and a univariate analysis was performed.

Furthermore, as an adjustment for bias, we implemented multiple regression analysis to clarify the factors associated with discomfort for the primary outcome. In this analysis, the objective variable was the discomfort score, and the explanatory variables were the probable factors relating to the discomfort.

In order to investigate the effect of heavy alcohol consumption on sedation, multiple regression analysis adjusted for the factors of discomfort was performed in the subgroups with and without sedation as an additional analysis. All statistical analyses were performed using EZR (ver1.37; Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). *P* value \< 0.05 was considered as statistically significant.

RESULTS
=======

The number of participants were 1792. Seventy-seven patients were excluded due to inadequate questionnaire responses; finally, 1715 patients were enrolled in this study. Table [1](#T1){ref-type="table"} includes the demographics of all participants by possible factors relating to discomfort. We were able to obtain all the data for the factors without any gaps. Overall, the median discomfort score and the interquartile range were 2 and 2-4, respectively, and 18% of the participants had high discomfort levels (score ≥ 6).

###### 

Participants' demographics (*n* = 1715)

  **Possible factors relating to discomfort**          **Mean (SD)**
  ---------------------------------------------------- ---------------
  Age                                                  59 (11)
  BMI                                                  23.5 (3.6)
  Height                                               163.1 (8.8)
  Possible factors relating to discomfort number (%)   
  Age                                                  
  ≤ 39                                                 80 (4.7)
  40-49                                                308 (18.0)
  50-59                                                431 (25.1)
  60-69                                                610 (35.6)
  ≥ 70                                                 286 (16.7)
  Male sex                                             950 (55%)
  BMI ≥ 25                                             503 (29.3)
  Height                                               
  \< 150 cm                                            114 (6.7)
  150-160 cm                                           546 (31.8)
  160-170 cm                                           644 (37.6)
  ≥ 170 cm                                             411 (24.0)
  Smoking status                                       
  Non-smoker                                           988 (57.6)
  Past-smoker                                          487 (28.4)
  Current-smoker                                       240 (14.0)
  Alcohol consumption                                  
  Non-drinker                                          761 (44.4)
  Normal drinker                                       812 (47.4)
  Heavy-drinker                                        142 (8.3)
  History of endoscopy                                 1602 (93.4)
  History of gastrectomy                               30 (1.8)
  Butylscopolamine administration                      511 (29.8)
  Biopsy performed                                     49 (2.9)
  Lugol's solution use                                 7 (0.4)
  Small diameter endoscope                             1657 (96.6)
  Hiatal hernia                                        775 (45.2)
  Sedative                                             
  None                                                 774 (45.1)
  Pethidine                                            797 (46.5)
  Midazolam                                            19 (1.1)
  Pethidine and midazolam                              125 (7.3)

BMI: Body mass index.

According to the univariate analysis in the non-sedated group, the factors associated with increased discomfort were young age (*P* \< 0.001), female sex (*P* \< 0.001), and no history of endoscopy (*P* \< 0.001); additionally, significant differences were also found for height (*P* = 0.007), smoking status (*P* = 0.003), and endoscopist (*P* \< 0.001) (Table [2](#T2){ref-type="table"}). With reference to the proportion of high discomfort (score ≥ 6) in the non-sedated group, young age (*P* \< 0.001), female sex (*P* = 0.03), and no history of endoscopy (*P* \< 0.001) were the factors related to increased discomfort; significant differences were also found for smoking status (*P* = 0.033) and endoscopists (*P* = 0.011) (Table [2](#T2){ref-type="table"}). For the sedated group, young age (*P* \< 0.001), female sex (*P* \< 0.001), and no history of endoscopy (*P* = 0.004) were the factors associated with increased discomfort; significant differences were also found for smoking status (*P* \< 0.001), type of sedation (*P* \< 0.001), and endoscopist (*P* = 0.027). There was a marginal difference based on alcohol consumption (*P* = 0.055) (Table [3](#T3){ref-type="table"}). Additionally, for the proportion of high discomfort in this group, young age (*P* \< 0.001) and no history of endoscopy (*P* = 0.018) were the factors associated with increased discomfort. Significant differences were also found based on alcohol intake (*P* = 0.001). However, there was only a marginal difference based on the smoking status (*P* = 0.055) (Table [3](#T3){ref-type="table"}).

###### 

Discomfort for each factor in the group without sedation (*n* = 774) and univariate analysis results

  **Discomfort score value median (quartile ranges)**   **Proportion of high discomfort (score** ≥ **6)**                                              
  ----------------------------------------------------- --------------------------------------------------- ------------------------ ----------------- ----------------------
  Age                                                                                                                                                  
  ≤ 39                                                  6 (4-8)                                             *P* \< 0.001             60.5% (23/38)     *P* \< 0.001
  40-49                                                 4 (4-6)                                             Kruskal-Wallis test      45.1% (51/113)    *χ*^2^ test
  50-59                                                 4 (2-6)                                                                      34.7% (66/190)    
  60-69                                                 4 (2-4)                                                                      18.3% (48/262)    
  ≥ 70                                                  2 (0-4)                                                                      9.9% (17/171)     
  Male sex                                              4 (2-4)                                             *P* \< 0.001             23.5% (130/554)   *P* = 0.003
  Female sex                                            4 (2-6)                                             Mann-Whitney *U* test    34.1% (75/220)    *χ*^2^ test
  BMI                                                                                                                                                  
  ≥ 25                                                  4 (2-6)                                             *P* = 0.796              27.2% (62/228)    *P* = 0.773
  \< 25                                                 4 (2-6)                                             Mann-Whitney *U* test    26.2% (143/546)   *χ*^2^ test
  Height                                                                                                                                               
  \< 150 cm                                             4 (2-5)                                             *P* = 0.007              25.7% (9/35)      *P* = 0.219
  150-160 cm                                            4 (2-6)                                             Kruskal-Wallis test      29.4% (53/180)    *χ*^2^ test
  160-170 cm                                            4 (2-4)                                                                      22.7% (75/330)    
  ≥ 170 cm                                              4 (2-6)                                                                      29.7% (68/229)    
  Non-smoker                                            4 (2-6)                                             *P* = 0.003              26.5% (104/393)   *P* = 0.033
  Past smoker                                           4 (2-4)                                             Kruskal-Wallis test      22.4% (57/255)    *χ*^2^ test
  Current smoker                                        4 (2-6)                                                                      34.9% (44/126)    
  Non-drinker                                           4 (2-6)                                             *P* = 0.098              29.4% (91/309)    *P* = 0.291
  Normal drinker                                        4 (2-4)                                             Kruskal-Wallis test      24.9% (96/386)    *χ*^2^ test
  Heavy drinker                                         4 (2-4)                                                                      22.8% (18/79)     
  History of endoscopy (+)                              4 (2-4)                                             *P* \< 0.001             24.8% (180/727)   *P* \< 0.001
  History of endoscopy (-)                              6 (4-7)                                             Mann-Whitney *U* test    53.2% (25/47)     *χ*^2^ test
  History of gastrectomy (+)                            2 (2-4)                                             *P* = 0.202              16.7% (3/18)      *P* = 0.428
  History of gastrectomy (-)                            4 (2-6)                                             Mann-Whitney *U* test    26.7% (202/756)   Fisher\'s exact test
  Butylscopolamine (+)                                  2 (2-4)                                             *P* = 0.115              20.6% (14/68)     *P* = 0.249
  Butylscopolamine (-)                                  4 (2-6)                                             (Mann-Whitney *U* test   27.1% (191/706)   *χ*^2^ test
  Biopsy performed (+)                                  4 (2-6)                                             *P* = 0.461              39.1% (9/23)      *P* = 0.163
  Biopsy performed (-)                                  4 (2-6)                                             Mann-Whitney *U* test    26.1% (196/751)   *χ*^2^ test
  Lugol's solution (+)                                  4 (2-6)                                             *P* = 0.950              40.0% (2/5)       *P* = 0.612
  Lugol's solution (-)                                  4 (2-6)                                             (Mann-Whitney *U* test   26.4% (203/769)   Fisher\'s exact test
  Endoscope                                                                                                                                            
  Normal diameter                                       4 (2-6)                                             *P* = 0.737              28.6% (6/21)      *P* = 0.826
  Small diameter                                        4 (2-6)                                             Mann-Whitney *U* test    26.4% (199/753)   *χ*^2^ test
  Hiatal hernia (+)                                     4 (2-6)                                             *P* = 0.257              27.6% (113/410)   *P* = 0.472
  Hiatal hernia (-)                                     4 (2-6)                                             Mann-Whitney *U* test    25.3% (92/364)    *χ*^2^ test
  Sedation agent                                                                                                                                       
  No use                                                4 (2-6)                                             \-                       26.5% (205/774)   \-
  Pethidine alone                                       \-                                                                           \-                
  Midazolam alone                                       \-                                                                           \-                
  Pethidine and Midazolam                               \-                                                                           \-                

Number of endoscopists: 27. Range of median score: 0 to 6. Proportion of high discomfort responses: 0 to 60% (details are omitted). Kruskal-Wallis test result for median score: *P* \< 0.001. *χ*^2^ test result for proportion of high discomfort: *P* = 0.011. BMI: Body mass index.

###### 

Discomfort for each factor in the sedation group (*n* = 941) and univariate analysis results

  **Discomfort score value median (quartile ranges)**   **Proportion of high discomfort (score 6 or higher)**                                             
  ----------------------------------------------------- ------------------------------------------------------- ----------------------- ----------------- ----------------------
  Age                                                                                                                                                     
  ≤ 39                                                  4 (2.5-6)                                               *P* \< 0.001            40.5% (17/42)     *P* \< 0.001
  40-49                                                 2 (2-4)                                                 Kruskal-Wallis test     17.9% (35/195)    *χ*^2^ test
  50-59                                                 2 (0-4)                                                                         10.8% (26/241)    
  60-69                                                 2 (0-4)                                                                         6.0% (21/348)     
  ≥ 70                                                  2 (0-2)                                                                         3.5% (4/115)      
  Male sex                                              2 (0-4)                                                 *P* \< 0.001            10.9% (43/396)    *P* = 0.942
  Female sex                                            2 (2-4)                                                 Mann-Whitney *U* test   11.0% (60/545)    *χ*^2^ test
  BMI                                                                                                                                                     
  ≥ 25                                                  2 (0-4)                                                 *P* = 0.155             11.3% (31/275)    *P* = 0.837
  \< 25                                                 2 (0-4)                                                 Mann-Whitney *U* test   10.8% (72/666)    *χ*^2^ test
  Height                                                                                                                                                  
  \< 150 cm                                             2 (1-4)                                                 *P* = 0.185             13.9% (11/79)     *P* = 0.109
  150-160 cm                                            2 (0-4)                                                 Kruskal-Wallis test     9.6% (35/366)     *χ*^2^ test
  160-170 cm                                            2 (0-4)                                                                         9.2% (29/314)     
  ≥ 170 cm                                              2 (0-4)                                                                         15.4% (28/182)    
  Non-smoker                                            2 (0-4)                                                 *P* \< 0.001            10.1% (60/595)    *P* = 0.055
  Past smoker                                           2 (0-4)                                                 Kruskal-Wallis test     9.9% (23/232)     *χ*^2^ test
  Current smoker                                        2 (2-4)                                                                         17.5% (20/114)    
  Non-drinker                                           2 (0-4)                                                 *P* = 0.055             9.5% (43/452)     *P* = 0.001
  Normal drinker                                        2 (0-4)                                                 Kruskal-Wallis test     10.3% (44/426)    *χ*^2^ test
  Heavy drinker                                         2 (1-5)                                                                         25.4% (16/63)     
  History of endoscopy (+)                              2 (0-4)                                                 *P* = 0.004             10.3% (90/875)    *P* = 0.018
  History of endoscopy (-)                              2 (2-4)                                                 Mann-Whitney U test     19.7% (13/66)     *χ*^2^ test
  History of gastrectomy (+)                            2 (0-2.5)                                               *P* = 0.477             16.7% (2/12)      *P* = 0.631
  History of gastrectomy (-)                            2 (0-4)                                                 Mann-Whitney *U* test   10.9% (101/929)   Fisher\'s exact test
  Butylscopolamine (+)                                  2 (0-4)                                                 *P* = 0.187             10.6% (47/443)    *P* = 0.755
  Butylscopolamine (-)                                  2 (0-4)                                                 Mann-Whitney *U* test   11.2% (56/498)    *χ*^2^ test
  Biopsy performed (+)                                  2 (0-3.5)                                               *P* = 0.287             11.5% (3/26)      *P* = 0.757
  Biopsy performed (-)                                  2 (0-4)                                                 Mann-Whitney *U* test   10.9% (100/915)   Fisher\'s exact test
  Lugol's solution (+)                                  1 (0.5-1.5)                                             *P* = 0.35              0.0% (0/2)        *P* = 1.00
  Lugol's solution (-)                                  2 (0-4)                                                 Mann-Whitney *U* test   11.0% (103/939)   Fisher\'s exact test
  Endoscope                                                                                                                                               
  Normal diameter                                       2 (2-4)                                                 *P* = 0.197             10.8% (4/37)      *P* = 1.00
  Small diameter                                        2 (0-4)                                                 Mann-Whitney *U* test   11.0% (99/904)    Fisher\'s exact test
  Hiatal hernia (+)                                     2 (0-4)                                                 *P* = 0.891             12.3% (45/365)    *P* = 0.279
  Hiatal hernia (-)                                     2 (0-4)                                                 Mann-Whitney *U* test   10.1% (58/576)    *χ*^2^ test
  Sedation agent                                                                                                                                          
  No use                                                \-                                                                              \-                
  Pethidine alone                                       2 (0-4)                                                 *P* \< 0.001            11.7% (93/797)    *P* = 0.186
  Midazolam alone                                       2 (0-4)                                                 Kruskal-Wallis test     10.5% (2/19)      Fisher\'s exact test
  Pethidine and Midazolam                               0 (0-2)                                                                         6.4% (8/125)      

Number of endoscopists: 27. Range of median score: 0 to 4. Range of proportion of high discomfort responses: 0 to 27.8% (details are omitted). Kruskal-Wallis test result for median score: *P* = 0.027. *χ*^2^ test result for proportion of high discomfort: *P* = 0.216. BMI: Body mass index.

Based on multiple regression analysis (Table [4](#T4){ref-type="table"}), young age (regression coefficient for -1 years: 0.08, *P* \< 0.001), female sex (regression coefficient: 0.45, *P* = 0.013), shorter height (regression coefficient for -1 cm: 0.02, *P* = 0.024), current smoking status (regression coefficient: 0.35, *P* = 0.036), and presence of hiatal hernia (regression coefficient: 0.34, *P* = 0.003) were the factors that significantly increased the discomfort in esophagogastroduodenoscopy. The use of sedation significantly reduced discomfort. Pethidine (regression coefficient: -1.47, *P* \< 0.001), midazolam (regression coefficient: -1.63, *P* = 0.001), and their combination (regression coefficient: -2.92, *P* \< 0.001) were found to significantly reduce the discomfort. The individual endoscopist performing the procedure was also associated with the discomfort (regression coefficient estimates: Maximum 2.78 differences). According to the multiple regression analysis performed in both groups, the regression coefficient of heavy alcohol consumption was 0.90 (*P* = 0.001) in the sedation group and 0.008 (*P* = 0.78) in the non-sedation group. Therefore, under sedation, the discomfort experienced by a heavy drinker was greater than that experienced by a non-heavy drinker.

###### 

Multiple regression analysis and impact of each factor for discomfort

                                 **Regression coefficient**   **Upper limit of 95%CI**   **Lower limit of 95%CI**   ***P* value**
  ------------------------------ ---------------------------- -------------------------- -------------------------- ---------------
  Age (+ 1)                      -0.08                        -0.09                      -0.07                      \< 0.001
  Sex (male)                     -0.45                        -0.79                      -0.10                      0.013
  BMI (+ 1)                      -0.002                       -0.03                      0.03                       0.903
  Height (+ 1)                   -0.02                        -0.04                      -0.003                     0.024
  Smoking status                                                                                                    
  Past smoker                    -0.06                        -0.32                      0.20                       0.638
  Current smoker                 0.35                         0.02                       0.67                       0.036
  Alcohol consumption                                                                                               
  Normal drinker                 -0.05                        -0.27                      0.18                       0.680
  Heavy drinker                  0.20                         -0.21                      0.61                       0.337
  Has no endoscopic experience   0.22                         -0.20                      0.65                       0.300
  History of gastrectomy         0.36                         -0.41                      1.14                       0.362
  Butylscopolamine use           -0.04                        -0.35                      0.27                       0.802
  Biopsy performed               0.11                         -0.51                      0.72                       0.729
  Lugol's solution use           1.02                         -0.61                      2.64                       0.221
  Normal diameter endoscope      0.48                         -0.09                      1.05                       0.101
  Hiatal hernia                  0.34                         0.11                       0.57                       0.003
  Sedation agent                                                                                                    
  Pethidine alone                -1.47                        -1.71                      -1.22                      \< 0.001
  Midazolam alone                -1.63                        -2.61                      -0.66                      0.001
  Pethidine and midazolam        -2.92                        -3.36                      -2.49                      \< 0.001

Maximum difference in discomfort among endoscopists (regression coefficient): 2.78 (details of each endoscopist were omitted). BMI: Body mass index.

DISCUSSION
==========

Based on the multiple regression analysis, the factors associated with increased discomfort in esophagogastroduodenoscopy were young age, female sex, short height, current smoking status, and hiatal hernia. Individual endoscopists were also related to the discomfort. Additionally, heavy alcohol consumption diminished sedation. This is consistent with the previous report that revealed young\[[@B4]-[@B7]\] and female patients\[[@B4],[@B5],[@B8],[@B9]\] have higher levels of discomfort. The high discomfort in younger patients is considered to be mainly due to gag reflex\[[@B10]\]. The high discomfort in women is considered due to a low pain threshold\[[@B11]\]. Additionally, it is reported that vomiting, belching, or retching increases significantly in patients with hiatal hernia\[[@B10]\], which can be the cause of the high levels of discomfort in such cases.

The results of the present study suggest that current smokers have increased discomfort due to esophagogastroduodenoscopy. Although smoking is considered a cause of gag reflex\[[@B12]\], smoking was not identified as a significant factor of discomfort in the previous studies\[[@B7],[@B9],[@B10]\]. Thus, current smoking status associated with increased discomfort has been newly identified in the present study, which may be due to the larger sample size of the present study. It is reported that smokers have chronic laryngitis\[[@B13]\]; hence, chronic irritation to the throat may be the cause of gag reflex in smokers. Additionally, since there was no difference in the discomfort experienced between past-smokers and non-smokers, smoking cessation could help eliminate the increasing discomfort. Although previous studies only investigated the discomfort or gag reflex based on body mass index as a body-type factor in\[[@B5],[@B9],[@B10]\]; short height may be related to high discomfort levels because the scope diameter is relatively large. Therefore, in this study, height was also included as a factor and was found to be significantly related to discomfort. Although this is a new finding of interest, univariate analysis for high discomfort was not significantly different, and the regression coefficient in multiple regression analysis is relatively small and, therefore, has less clinical relevance.

Sedation was useful as it significantly reduced discomfort, and the use of either pethidine, midazolam, or their combination was effective. However, heavy alcohol consumption reduced the effect of sedation. Sedation is reported to be less effective in heavy drinkers\[[@B14]\]. Previous studies have shown that the requisite doses of benzodiazepines and the combination of benzodiazepine and opioid are higher for heavy drinkers than for others\[[@B15],[@B16]\]. Unlike previous reports, in the majority of the cases in the present study, pethidine was used and was found to be less effective in heavy drinkers. Therefore, we believe that discomfort can be predicted from age, sex, smoking status, and alcohol consumption, which can be easily obtained before examination.

The limitation of this study is the possibility of a selection bias since it is a retrospective cross-sectional study from a single facility. However, various information was analyzed in connection with the health check-up data in many participants. Additionally, anxiety and pharyngeal sensitivity, which were identified as factors of discomfort in the previous studies, could not be analyzed before the examination\[[@B4]-[@B7],[@B9]\]. However, anxiety and pharyngeal sensitivity are rarely evaluated in general practice; therefore, it is meaningful to investigate the factor of discomfort by the information obtained ordinarily in daily practice. The strengths of the present study are that it is a large-size study, and smoking status was identified for the first time as a contributing factor to discomfort in esophagogastroduodenoscopy.

In conclusion, young and female patients experience more discomfort in esophagogastroduodenoscopy. Furthermore, the discomfort in current smokers may increase. Additionally, heavy alcohol consumption reduces the effect of sedatives. These factors are useful because they can be easily obtained, and we can take remedial measures for reducing discomfort.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Discomfort due to esophagogastroduodenoscopy contributes to a negative experience and reduces the patients' satisfaction. Therefore, it is important to reduce discomfort as much as possible. By identifying the factors that cause discomfort, we can take remedial measures such as using sedation.

Research motivation
-------------------

However, not all factors of discomfort have been elucidated yet. Most previous studies have conducted investigations only in several hundred subjects, which is a relatively small sample.

Research objectives
-------------------

The aim of this study was to elucidate the contributing factors of discomfort in transoral esophagogastroduodenoscopy by a large-scale cross-sectional study.

Research methods
----------------

This study was a retrospective observational study using a questionnaire for the improvement of hospital services. Discomfort was evaluated using a face scale between 0 and 10 with a 6-level questionnaire. Univariate and multiple regression analyses were performed to investigate the factors related to the discomfort in esophagogastroduodenoscopy. The primary outcome was the result of a multiple regression. In this analysis, the objective variable was the discomfort score and the explanatory variables were age, sex, height, body mass index, smoking status, alcohol intake, hiatal hernia, history of gastrectomy, biopsy during examination, Lugol's solution usage, administration of butylscopolamine with/without a sedative (pethidine, midazolam, or both), endoscope model, history of endoscopy, and endoscopists.

Research results
----------------

Finally, 1715 patients were enrolled in this study. Based on multiple regression analysis, young age, female sex, shorter height, current smoking status, and presence of hiatal hernia \[regression coefficients of 0.08, *P* \< 0.001 (for -1 years); 0.45, *P* = 0.013; 0.02, *P* = 0.024 (for -1 cm); 0.35, *P* = 0.036; and 0.34, *P* = 0.003, respectively\] were factors that significantly increased the discomfort in esophagogastroduodenoscopy. Alternatively, sedation significantly reduced discomfort; pethidine (regression coefficient: -1.47, *P* \< 0.001) and midazolam (regression coefficient: -1.63, *P* = 0.001) both individually and in combination (regression coefficient: -2.92, *P* \< 0.001) significantly reduced the discomfort. A difference in the endoscopist performing the procedure was also associated with discomfort. Additionally, for the proportion of a high discomfort level (score ≥ 6) in the sedated group, significant differences were also found based on alcohol intake in univariate analyses (*P* = 0.001).

Research conclusions
--------------------

The present study clearly identified the factors associated with discomfort in esophagogastroduodenoscopy using a large-size cross-sectional study. Young age, female sex, and current smoking were identified as the contributive factors. Smoking status was a newly identified predictor of this study. Furthermore, heavy alcohol consumption was noted to diminish the effect of the sedative(s). These factors are useful because they can be easily obtained, and we can take remedial measures for reducing discomfort.

Research perspectives
---------------------

Prospective research is needed to clarify whether predicting discomfort and taking measures to alleviate it can effectively increase patient satisfaction.
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